Okamoto syndrome

From WikiMD's WELLNESSPEDIA

Okamoto syndrome

Okamoto syndrome is a rare genetic disorder characterized by a variety of physical and developmental abnormalities. It was first described by Nobuhiko Okamoto in 1997. The syndrome is also known as Okamoto syndrome 1 and is caused by mutations in the HNRNPK gene.

Clinical Features[edit]

Individuals with Okamoto syndrome typically present with a range of clinical features, including:

Genetics[edit]

Okamoto syndrome is inherited in an autosomal dominant manner. The condition is caused by mutations in the HNRNPK gene, which is located on chromosome 9. This gene encodes a protein that is involved in various cellular processes, including RNA processing and gene expression.

Diagnosis[edit]

The diagnosis of Okamoto syndrome is based on clinical evaluation and the identification of characteristic features. Genetic testing can confirm the diagnosis by detecting mutations in the HNRNPK gene. Prenatal diagnosis may be possible if the mutation in the family is known.

Management[edit]

There is no cure for Okamoto syndrome, and treatment is symptomatic and supportive. Management may include:

Prognosis[edit]

The prognosis for individuals with Okamoto syndrome varies depending on the severity of the symptoms and the presence of associated complications. Early diagnosis and intervention can improve the quality of life for affected individuals.

See Also[edit]

References[edit]


External Links[edit]

-


Medical condition






















Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.